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Contribution of the R-Ras2 GTP-binding protein
to primary breast tumorigenesis and late-stage
metastatic disease
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Enrique de A´lava1,2,4, Balbino Alarco´n5, Mercedes Dosil1,2,6 & Xose´ R. Bustelo1,2
R-Ras2 is a transforming GTPase that shares downstream effectors with Ras subfamily
proteins. However, little information exists about the function of this protein in tumorigenesis
and its signalling overlap with classical Ras GTPases. Here we show, by combining loss- and
gain-of-function studies in breast cancer cells, mammary epithelial cells and mouse models,
that endogenous R-Ras2 has a role in both primary breast tumorigenesis and the late
metastatic steps of cancer cells in the lung parenchyma. R-Ras2 drives tumorigenesis in a
phosphatidylinostiol-3 kinase (PI3K)-dependent and signalling autonomous manner. By
contrast, its prometastatic role requires other priming oncogenic signals and the engagement
of several downstream elements. R-Ras2 function is required even in cancer cells exhibiting
constitutive activation of classical Ras proteins, indicating that these GTPases are not
functionally redundant. Our results also suggest that application of long-term R-Ras2
therapies will result in the development of compensatory mechanisms in breast tumours.
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R
-Ras2 (also known as TC21) is a GTP-binding protein that,
together with R-Ras1 and R-Ras3, forms part of the R-Ras
GTPase subfamily1. This protein is the closest relative
to classical Ras GTPases according to structural similarity
criteria and, in fact, is the only Ras superfamily member that
shows transforming activities similar to Ras oncoproteins2–7.
Experiments using constitutively active versions of this protein
revealed that R-Ras2 shares many Ras downstream signalling
elements, including phosphatidylinostiol-3 kinases (PI3Ks)7–10,
the Ral GDP dissociation stimulator (GDS)7,11 and, in a cell type-
speciﬁc manner, Raf kinases4–6,12,13. These properties led to the
initial idea that this GTPase could represent an alternative avenue
to stimulate the Ras pathway in tumours. In this context, R-Ras2
was considered as potentially important for breast tumorigenesis
based on its frequent overexpression in human cancer cell lines
and, in addition, its ability to drive transformation when
expressed in immortalized breast cells14–17. Despite this, the
interest on this GTPase faded away subsequently due to the
absence of oncogenic RRAS2 gene mutations in tumours.
However, recent reports have revived the interest on this
protein in mammary gland-related processes. Thus, the analysis
of Rras2 / mice has revealed that this GTPase plays proactive
roles during mammary gland development18. Furthermore,
recent observations have indicated that R-RAS2 could
contribute to tamoxifen resistance19,20, thus suggesting that the
inactivation of this pathway could be beneﬁcial for patients with
oestrogen receptor-positive breast tumours. It should be noted,
however, that the systemic loss of R-Ras2 leads to unexpected
protumorigenic effects in the case of mouse neuroﬁbroma21 that,
if reproduced in other cancer types and in humans, may limit the
interest of anti-R-Ras2-based therapies. Unfortunately, no
information exists about the pros and cons of inactivating
endogenous R-Ras2 in breast cancer in vivo and, therefore, about
the actual therapeutic interest of this signalling route.
Furthermore, as most of the work done with R-Ras2 has been
based on the use of constitutively active versions and ectopic
systems, we still have very few clues about the actual role of the
endogenous protein and its functional redundancy with classical
Ras GTPases. For the reasons stated above, we decided to revisit
the function of R-Ras2 in different breast tumour subtypes
using a comprehensive collection of genetic, signalling and
animal model experiments. In the present study, we show that
R-Ras2 has a role in the primary tumorigenesis and late
metastatic steps of breast cancer cells. Such functions are
required even when cancer cells have constitutive activation of
classical Ras GTPases. Moreover, we show that the speciﬁc
contribution of R-Ras2 to the overall transformation process is
highly dependent on the cell type and malignant trait analysed.
Our results also indicate that R-Ras2-based therapies will
probably result in tumour recurrence through activation
of signalling compensatory mechanisms.
Results
R-Ras2 affects primary tumorigenesis of breast cancer cells. To
evaluate the role of endogenous R-Ras2 in breast cancer and its
redundancy with classical Ras proteins, we ﬁrst used short hairpin
RNA (shRNA) techniques to knock down the endogenous tran-
scripts of this GTPase in both human MDA-MB-231-Luc and
mouse 4T1 breast cancer cells. These cells represent good tools to
address functional redundancy issues, because they exhibit con-
stitutive activation of classical Ras proteins due to the presence of
either oncogenic mutations (MDA-MB-231-Luc cells)22,23 or
autocrine signalling loops (4T1 cells)24. These cell lines also differ
in metastatic potential, thus facilitating the use of both gain- and
loss-of-function approaches to analyse the role of R-Ras2 in
this process25. To rule out spurious effects derived from the
cell-selection process, we used independent cell pools (labelled as
‘p1’ and ‘p2’) and clones (labelled as ‘c1’, ‘c2’ and ‘c3’) in these
experiments. In addition, we used ‘rescued’ knockdown cell lines
expressing a haemagglutinin (HA)-tagged version of human
R-RAS2. When appropriate, we used cell line derivatives
expressing a constitutively active version (G23V mutant) of
HA-R-RAS2. A summary of all the MDA-MB-231-Luc and 4T1
cell lines used in this study can be found in Supplementary
Tables 1 and 2, respectively. Effective elimination or ectopic
expression of indicated R-Ras2 proteins was veriﬁed by
immunoblot analyses (Supplementary Fig. 1).
We observed that all MDA-M-231-Luc (KDRRAS2.p1 and
KDRRAS2.p2; Fig. 1a–d) and 4T1 (KDRras2.p1, KDRras2.c1,
KDRras2.c2 and KDRras2.c3; Fig. 1e,f) knockdown cells exhibited
very low tumorigenicity when transplanted orthotopically in
recipient mice. This was not due to off-target shRNA effects,
because the expression of wild-type R-RAS2 (Supplementary
Fig. 1b,d) rescued the in vivo tumorigenicity of both MDA-MB-
231-Luc (Fig. 1c,d; see KDRRAS2.p1þR-RAS2 cell line) and 4T1
(Fig. 1f, bottom graph; see KDRras2.c1þR-RAS2 cell line)
knockdown cells. The slow growth kinetics of tumours derived
from R-Ras2-depleted cells were due to low proliferative and
neoangiogenic rates rather than to enhanced apoptosis
(Supplementary Fig. 2). These results indicate that R-Ras2 is
important for breast tumorigenesis even under constitutive Ras
signalling conditions. Consistent with this lack of functional
redundancy, we also observed that the ectopic expression of HA-
R-RAS2G23V further increased the in vivo tumorigenicity of
K-RASG13D- and B-RAFG464V-positive MDA-MB-231-Luc cells
(Fig. 1c,d; see MDAþR-RAS2G23V cells). This was associated
with higher proliferative and angiogenic rates in tumours during
their exponential growth phase (Supplementary Fig. 2d,e). These
features were lost at later stages (Supplementary Fig. 2a,b),
probably as a result of the very large size achieved by the tumour
mass at that time (see above, Fig. 1c,d).
R-Ras2 is involved in late metastatic steps. As 4T1 cells are
highly metastatic, we also examined the presence of metastasis in
tumour-bearing animals at the end of the experiments shown in
Fig. 1. We observed that mice orthotopically transplanted with
Rras2-knockdown 4T1 cells seldom showed metastatic nodules in
their lungs (Table 1). This was not due to the lower growth rates
of these tumours, because Rras2-knockdown 4T1 cells could not
form metastasis in the lung even when intravenously injected in
mice (Fig. 2a–c). The metastatic defects shown by Rras2-knock-
down cells in these two experimental systems were eliminated on
expression of wild-type R-RAS2 in them (Table 1 and Fig. 2b,c).
We also observed that ectopic R-RAS2G23V enhanced the
metastatic properties of parental 4T1 cells (Fig. 2d,e and
Supplementary Fig. 1d; see 4T1þR-RAS2G23V). Even most
notably, it triggered the acquisition of metastatic properties
in the otherwise non-metastatic MDA-MB-231-Luc cell line
(Table 1; Fig. 2f).
The metastatic process involves a large number of steps,
including lymph node inﬁltration, intravasation, extravasation
and the subsequent survival and expansion of cancer cells in
peripheral niches26,27. Using a quantitative reverse transcriptase–
PCR (qRT–PCR) approach to quantify the presence of cancer
cells in tissues, we observed that R-Ras2 was not required for the
intravasation or lymph node dissemination of 4T1 cells
(Supplementary Fig. 3a). We also observed that intravenously
injected Rras2-knockdown cells inﬁltrated the lung parenchyma
at rates similar to control cells (Supplementary Fig. 3b,c),
thus ruling out its implication in the extravasation process.
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To investigate its involvement in the post-extravasation phase, we
analysed the effect of ectopic R-RASG23V in mouse breast cancer
cells that had speciﬁc defects in either the pre-extravasation
(168FARN cells) or post-extravasation (4TO7 cells) steps
(Supplementary Fig. 3d,e)24. Although inducing similar
protumorigenic effects in these two lines (Supplementary
Fig. 3f), we observed that R-RAS2G23V could restore metastatic
properties when expressed in 4TO7 but not in 168FARN cells
(Supplementary Fig. 3g–i). These results indicate that the
function of R-Ras2 in the metastatic process is circumscribed to
the post-extravasation phase.
R-Ras2 activates PI3K even in KRAS-transformed cells. To
understand the reason for the non-redundant role of R-Ras2 and
Ras proteins in breast cancer cells, we next investigated the
activation status of the downstream Erk, Akt and Ral-a signalling
pathways in our collection of breast cancer cell lines. Consistent
with the chronic activation of Ras proteins, we observed that
control MDA-MB-231-Luc (Fig. 3a; top panel, compare lanes 1
and 5) and 4T1 (Supplementary Fig. 4a; top panel, compare lanes
1 and 5; Supplementary Fig. 4b, top panel, compare lanes 1 and 7)
cells exhibited high amounts of phosphorylated Erk even under
serum starvation conditions. Same results were obtained with
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Figure 1 | R-Ras2 plays roles in primary tumorigenesis. (a) Example of a primary tumorigenesis experiment with indicated orthotopically transplanted
MDA-MB-231-Luc cells. Scale of bioluminescence signals obtained in tumour-bearing animals is shown at the bottom. (b) Growth kinetics of tumours
formed by indicated MDA-MB-231-Luc cells. ***Pr0.001 relative to values obtained by control cells at ﬁnal experimental time point (number of
independent transplants is indicated in the ﬁgure); t-test. (c) Example of a primary tumorigenesis experiment with indicated MDA-MB-231-Luc cells.
(d) Growth kinetics of tumours formed by indicated MDA-MB-231-Luc cells. ***Pr0.001 relative to values obtained by control cells at the ﬁnal
experimental time point (number of independent transplants is indicated in the ﬁgure); t-test. (e) Example of tumours formed by indicated 4T1 cells.
t, tumour; *, lymph node. (f) Growth kinetics of tumours formed by indicated 4T1 cells. **Pr0.01; ***Pr0.001 relative to values obtained by either control
cells or indicated experimental pairs (in brackets) at ﬁnal experimental time point (number of independent transplants is indicated in the ﬁgure);
t-test. In panels b, d and f, experimental values are given as mean± s.e.m.
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168FARN cells (Supplementary Fig. 4b, upper panel, compare
lanes 5 and 11). By contrast, 4TO7 cells showed serum-dependent
Erk phosphorylation (Supplementary Fig. 4b; upper panel, com-
pare lanes 3 and 9). All these cells unexpectedly showed serum-
dependent phosphorylation of Akt (Fig. 3a and Supplementary
Fig. 4a; third and fourth panels from top), indicating that the
stimulation of this pathway was not directly linked to Ras acti-
vation status. These analyses also revealed that ectopic
R-RAS2G23V promoted a marked hyperphosphorylation of Akt in
all cell lines tested. This effect was still serum-dependent in the
case of 4T1 (Supplementary Fig. 4a, third and fourth panel from
top, compare lanes 4 and 8) and 4TO7 (Supplementary Fig. 4b,
third and fourth panels from top, compare lanes 4 and 10) cells,
suggesting that R-RAS2G23V is still subjected to some kind of
upstream regulation in these cell lines. The stimulation of this
signalling branch was speciﬁc, because R-RAS2G23V did not
induce any signiﬁcant change in either Erk1/2 phosphorylation
(Fig. 3a and Supplementary Fig. 4a,b; top panels) or Ral-a activity
(Supplementary Fig. 4c). Hence, these results indicate that
R-RAS2G23V contributes to the stimulation of the PI3K/Akt
route even in breast cancer cells with constitutive activation of
classical Ras proteins. Consistent with this, we observed that
ectopic R-RAS2G23V also regulated a large number of Akt
downstream elements (Supplementary Fig. 4d–g). Overexpressed
wild-type R-RAS2 also elicited a mild, serum-dependent elevation
in the amount of Akt phosphorylation in the ‘rescued’
knockdown cells (Fig. 3a and Supplementary Fig. 4a; third
and fourth panels from top, compare lanes 1 and 3, and lanes 5
and 7). The use of PI3K isoform-speciﬁc inhibitors revealed
that the activation of Akt by R-RAS2G23V was mainly mediated
by PI3Ka in both MDA-MB-231-Luc (Fig. 3b) and 4T1
(Supplementary Fig. 4h) cells.
Unlike the above cases, we did not ﬁnd any obvious alteration
in the Akt signalling pathway in knockdown cells (Fig. 3a and
Supplementary Fig. 4a, compare lanes 1–2 and lanes 5–6). As this
could be due to masking effects derived from the presence
and absence of mitogens under the exponentially growing and
serum-free culture conditions used, we decided to analyse the
kinetics of activation of Akt on the stimulation of serum-starved
Table 1 | Metastasis formed by indicated 4T1 and
MDA-MB-231-Luc cell lines in the lung and spleen
on orthotopic transplantation in mammary pads.
Cell line* Lung Spleen
4T1-control 11/13w 8/13
KDRras2.c1 1/12 1/12
KDRras2.c2 1/6 0/6
KDRras2.c3 1/6 0/6
KDRras2.c1þ R-RAS2 4/7 5/7
MDA-control 1/6 0/0
MDAþ R-RAS2G23V 6/7 0/0
*For information about each cell line, see Supplementary Tables 1 and 2.
wThe x/y ratio indicates number of animals that scored positive for metastasis in indicated
tissues (x) versus the total number of mice analysed in experiments (y).
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Figure 2 | R-Ras2 is important for breast cancer cell metastasis. (a) Lung metastases formed by indicated intravenously injected 4T1 cells. **Pr0.01
relative to control cell line (n¼ 6, 12, 5 and 6 for 4T1-Control, KDRras2.c1, KDRras2.c2 and KDRras2.c3 cells, respectively); t-test. (b) Example of metastatic
nodules (white spots) formed in lungs on intravenous injection of indicated 4T1 cells. (c) Lung metastases formed by indicated intravenously injected 4T1
cells. ***Pr0.001 relative to control cells (n¼4, 5 and 6 for 4T1-Control, KDRras2.c1 and KDRras2.c1þR-RAS2 cells, respectively); t-test. (d) Examples of
lung metastatic nodules formed by indicated intravenously injected 4T1 cell lines. (e) Lung metastases formed by indicated intravenously injected 4T1 cells.
***Pr0.001 relative to control cells (n¼ 5). In this experiment, we injected suboptimal (5 104) numbers of 4T1 cells to pick up differences in metastatic
node formation. (f) Example of lung metastatic behaviour of indicated intravenously injected MDA-MB-231-Luc cells (n¼6). In panels a, c and e,
experimental values are given as mean±s.e.m.
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RRAS2-knockdown MDA-MB-231 cells with either insulin-like
growth factor 1 (IGF1) or epidermal growth factor (EGF). These
mitogens promote endogenous R-RAS2 activation, as demon-
strated by pull-down experiments using a glutathione S-
transferase–Ral GDS fusion protein that speciﬁcally recognizes
GTP-bound R-RAS2 (Supplementary Fig. 4i)11. As a control for
these experiments, we decided to use a stable MDA-MB-231-Luc
cell line (referred to hereafter as KDPIK3CA) in which the
endogenous PIK3CA transcript was reducedE60% using shRNA
techniques (Supplementary Fig. 4j). These cells showed no
statistically signiﬁcant variations in the relative amounts of
PIK3CB and PIK3CG mRNAs when compared with controls
(n¼ 3, PZ0.05, t-test). However, they did show a small
upregulation (1.85±0.09-fold) of PIK3CD transcripts (Pr0.05,
n¼ 3, t-test). Using immunoblot analyses, we found that the
depletion of endogenous R-RAS2 and PI3Ka reduced the IGF1-
and EGF-mediated phosphorylation of AKT speciﬁcally in the
mTORC2-dependent S473 site (Fig. 3c–f, compare ﬁrst and
second panels from top in each case). Such effect was more
dramatic when the mitogen-triggered phosphorylation of
FOXO1/3a was analysed in the same cell lysates (Fig. 3c–f).
We also observed, using immunohistochemical techniques,
that MDA-MB-231-Luc cell-derived tumours exhibited reduced
phosphorylation levels of both FOXO1/3a and S6RP when
compared with controls (Supplementary Fig. 5). They also
displayed increased immunoreactivity levels for p53
(Supplementary Fig. 5), a tumour suppressor normally degraded
through the PI3K/Akt/Mdm2 signalling axis (Supplementary
Fig. 4d). Such defects were absent in tumours generated by
‘rescued’ RRAS2-knockdown cells (Supplementary Fig. 5). A
tendency to a slight variation for the above markers was also
observed in tumours generated by MDAþR-RAS2G23V cells
(Supplementary Fig. 5). Taken together, these results indicate that
R-Ras2 is important for the activation of a fraction of the PI3Ka
present in KRAS-transformed breast cancer cells.
R-Ras2 is important for protein translation in cancer cells.
MDA-MB-231 and 4T1 knockdown cells were unexpectedly quite
similar to appropriate controls in terms of proliferative activity
(Supplementary Fig. 6a,b), survival to anoikis (Supplementary
Fig. 6c,d), the transcriptome (Supplementary Fig. 6e) and the
proteome (Supplementary Fig. 6f; Supplementary Data 1). These
results indicated that the alterations in tumour growth seen
in vivo could not be due to intrinsic alterations in any of the
above biological processes. This led us to analyse other potential
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R-Ras2 and PI3K/Akt/mTORC1-dependent routes that could
contribute to the in vivo transforming properties of breast cancer
cells. Consistent with the role of this signalling axis in protein
synthesis regulation, we found that RRAS2- (Fig. 4a,b), Rras2-
(Fig. 4c,d) and PIK3CA- (Fig. 4e,f) knockdown cells, but not the
‘rescued’ knockdown cells (Fig. 4e,f), had less efﬁcient protein
synthesis than controls when tested using [35S]-methionine
labelling experiments. In agreement with the implication of the
PI3K signalling pathway in this process, the ectopic expression of
a constitutively active version of PI3Ka (PI3KaCAAX mutant)28
restored normal protein biosynthesis in MDA-MB-231-Luc
knockdown cells (Fig. 4e,f; see KDRRAS2.p1þPI3KaCAAX
cells). Corroborating these observations, we observed that all
R-Ras2-deﬁcient breast cancer cells had lower polysome over
monosome percentages than controls (Fig. 4g,h). As above, such
defect was not observed in knockdown cells expressing either
PI3KaCAAX (Fig. 4g,h) or wild-type R-RAS2 (Fig. 4h). Thus, in
cell culture, endogenous R-Ras2 seems to contribute primarily to
optimal protein biosynthesis in the two breast cancer cell lines
under study.
R-Ras2 promotes tumorigenesis in a PI3K-dependent manner.
Given the rescue effect elicited by PI3KaCAAX in the above
experiments, we next investigated whether the ectopic expression
of this lipid kinase could also eliminate the in vivo defects
exhibited by R-Ras2-depleted breast cancer cells. PI3KaCAAX did
restore the in vivo tumorigenicity of both knockdown cell lines
(Fig. 5a–d) and, in the case of MDA-MB-231-Luc cells, promoted
even higher tumorigenic activities than those normally shown by
parental counterparts (Fig. 5a,b). The differential effect of
PI3KaCAAX in MDA-MB-231-Luc and 4T1 cells correlated well
with the activation level of the PI3Ka/Akt signalling pathway
achieved in each case (Fig. 5e,f). Conﬁrming the involvement of
PI3Ka in R-Ras2-dependent tumorigenesis, we observed that the
partial knockdown of the endogenous PIK3CA transcript reduced
the in vivo transforming activity of R-RASG23V-expressing
MDA-MB-231-Luc cells (Fig. 5g,h, see MDAþR-RAS2G23Vþ
KDPIK3CA cells). However, these cells still formed tumours with
growth kinetics similar to control cells, a result probably derived
from the residual amounts of endogenous PI3Ka activity present
in MDAþR-RAS2G23VþKDPIK3CA cells (Fig. 5e, compare
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lanes 1 and 5). The depletion of endogenous PI3Ka also reduced
in vivo tumorigenic activity of parental cells (Fig. 5a,b). As in the
case of the R-Ras2 depletion (Supplementary Fig. 6a,b), the
in vivo tumorigenic defects shown by PI3Ka-deﬁcient cells could
not be attributed to reduced in vitro proliferation rates (Fig. 5i).
R-Ras2 uses different downstream effectors during metastasis.
Further analyses of tumour-bearing animals described in Fig. 5
revealed that PI3KaCAAX contributed differently to the metastatic
properties of 4T1 and MDA-MB-231-Luc cells. In the former
case, ectopic PI3KaCAAX could not restore the metastatic dis-
semination of Rras2-knockdown 4T1 cells to the lung (Table 2).
This was not due to negative effects induced by this mutant
protein, because PI3KaCAAX did not impair the metastatic
properties of parental cells (Table 2). Similar results were found
using intravenously injected cells (Fig. 6a,b). These results indi-
cate that R-Ras2 is probably involved in two post-extravasation
steps that are different according to PI3K signalling requirements.
This additional signalling route entails hitherto unknown
downstream elements, as our prior signalling data exclude the
direct participation of the Raf/Erk and RalGDS/Ral-a axes in this
process (Fig. 3 and Supplementary Fig. 4a–c). Consistent with
this, we observed using rescue experiments with a number of
R-RAS2 switch mutant versions7 that the interaction with PI3K,
but not with RalGDS, was important to maintain the R-Ras2-
dependent metastatic phenotype of 4T1 cells (Supplementary
Fig. 7). In the case of MDA-MB-231-Luc cells, we observed that
PI3KaCAAX did trigger the acquisition of metastatic properties
(Table 2; Fig. 6c). Conversely, the partial elimination of the
endogenous PIK3CA transcript was sufﬁcient to impair the
metastatic phenotype induced by ectopic R-RAS2G23V in these
cells (Table 2). These results indicate that R-Ras2 uses PI3Ka and
other downstream elements to support metastatic traits in breast
cancer cells (see Discussion).
R-Ras2 promotes tumorigenesis in an autonomous manner. To
check the signalling autonomy of R-Ras2 in breast cancer
initiation, we investigated the effect of ectopically expressing
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R-RAS2G23V in primary mammary epithelial cells (MECs). The
lentiviral-mediated expression of this protein in these cells
(Supplementary Fig. 8a) led to the activation of the PI3K/Akt
route (Supplementary Fig. 8b) and increased rates of PI3K-
dependent proliferation (Supplementary Fig. 8c–g). This mito-
genic effect was both serum- (Supplementary Fig. 8d,e) and Erk-
independent (Supplementary Fig. 8f,g). In agreement with this,
we did not see any upregulation of Erk proteins under these
conditions (Supplementary Fig. 8b). Similar effects were seen with
PI3KaCAAX-expressing MECs (Supplementary Fig. 8b,f,g). On
orthotopic transplantation, we observed that R-RAS2G23V-
expressing MECs generated glands with extensive ductal
branching and very high numbers of terminal lobular-alveolar
units (Fig. 7a). They also developed mammary tumours at high
penetrance (six out of eight implanted samples) on very short
latency periods (Fig. 7b,c). MECs infected with an empty lenti-
virus formed normal, non-tumorigenic mammary gland trees in
recipient mice (Fig. 7a). Thus, these results indicate that R-Ras2-
derived signals are sufﬁcient to trigger the transformation of
primary MECs both in vitro and in vivo.
R-Ras2 promotes metastasis in a non-autonomous manner.
The examination of mice with breast tumours derived from
implanted, R-RAS2G23V-expressing MECs revealed no metastatic
nodules or micrometastases in peripheral tissues, indicating that
R-Ras2 was not fully autonomous to drive the de novo acquisition
of metastatic traits. To distinguish if R-Ras2 did not play any
metastasis-related role in primary cells or, alternatively, whether
such role was subsidiary to the induction of metastatic traits by
other oncogenic signals, we investigated the effect of the Rras2
gene deﬁciency in primary MECs transformed on the lentiviral-
mediated expression of the polyoma middle T antigen (PyMT).
Probably as a consequence of the PyMT-mediated activation of
PI3Ka29, we observed that orthotopically transplanted
PyMTþ ;Rras2 / MECs could form tumours more efﬁciently
than the immortalized breast cancer cells used in prior assays
(Fig. 7d,e). Despite this, they still induced tumours at slightly
lower kinetics than PyMTþ ;Rras2þ /þ -transformed MECs
(Fig. 7d,e). By contrast, the tumours generated by
PyMTþ ;Rras2 / MECs were conspicuously much less
metastatic than those generated by the wild-type counterparts
(Fig. 7f,g). The same metastatic defect was observed when cells
isolated from those tumours were expanded in culture and
injected intravenously in recipient mice (Fig. 7h,i). These
observations indicate that R-Ras2 is required to maintain the
metastatic phenotype triggered by other oncogenic signals rather
than in the de novo induction of metastatic traits in primary cells.
Endogenous R-Ras2 is important for Her2 tumorigenesis. To
assess the actual role of R-Ras2 in breast cancer under more
physiological conditions, we ﬁnally used the mouse mammary
tumour virus (MMTV)-Her2tg mammary tumorigenesis model.
In this transgenic system, the overexpression of the wild-type
Her2 receptor (also known as Neu and Erbb2) in breast
epithelial cells triggers mammary gland hyperplasia and,
eventually, breast cancer. Thus, it recapitulates the transforming
events that take place in human Her2þ breast tumours, a
frequent PI3Ka/Akt-dependent breast cancer subtype30,31. To
investigate the participation of R-Ras2 in this stepwise
tumorigenic programme, we ﬁrst analysed the structure of
pre-neoplasic mammary glands in cohorts of pubertal MMTV-
Her2tg;Rras2þ /þ and MMTV-Her2tg;Rras2 / female mice.
This stage was selected because puberty is the period in which
ducts undergo a major morphogenetic programme that
eventually leads to the formation of the adult mammary
gland32. At this stage, glands from MMTV-Her2tg;Rras2 /
mice were smaller and less extended longitudinally than those
Table 2 | Metastasis formed by indicated 4T1 and
MDA-MB-231-Luc cell lines on orthotopic transplantation
in mammary pads.
Cell line* Lung Spleen
4T1-control 3/3w 3/3
KDRras2.c1 0/3 0/3
KDRras2.c1þ PI3KaCAAX 0/6 1/6
4T1þ PI3KaCAAX 6/6 6/6
MDA-control 1/4 0/4
KDRRAS2.p1 0/4 0/4
KDRRAS2.p1þ PI3KaCAAX 4/4 0/4
MDAþ R-RAS2G23V 3/4 0/4
MDAþ R-RAS2G23Vþ KDPIK3CA 0/4 0/4
*For information about each cell line, see Supplementary Tables 1 and 2.
wThe x/y ratio indicates number of animals that scored positive for metastasis in indicated
tissues (x) versus the total number of mice analysed in experiments (y).
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from MMTV-Her2tg;Rras2þ /þ mice (Fig. 8a,b). In addition, they
showed reduced numbers of terminal end buds (TEBs) (Fig. 8a,b),
the structures responsible for duct bifurcation and elongation
during this developmental period32. This phenotype is highly
reminiscent of the developmental defects shown by single
Rras2 / knockout mice at the same age18. In the post-
pubertal period, glands from MMTV-Her2tg;Rras2 / mice
were still slightly smaller (Fig. 8a,b) and lacked the extensive
secondary and tertiary ductal branching typically observed at this
developmental stage in glands from MMTV-Her2tg mice
(Fig. 8a), indicating that R-Ras2 is important for the premature
lobulo-alveolar differentiation induced by overexpressed Her2 in
post-pubertal mammary glands. This was a pathological-, Her2-
speciﬁc function for R-Ras2, because mammary glands of
Rras2 / mice do not show developmental defects at this
stage18. To assess the status of PI3K and Erk in this system, we
isolated MECs from prepubertal control and MMTV-
Her2tg;Rras2 / mice and, on a short-term starvation period,
stimulated them with EGF for the indicated periods of time.
We observed that Rras2-deﬁcient MECs showed reduced Akt
phosphorylation under these conditions. By contrast, the total
amount and kinetics of Erk phosphorylation were not affected
(Fig. 8c).
When analysed in long-term experiments, we found that
MMTV-Her2tg;Rras2 / female mice developed mammary
tumours at much lower frequencies than MMTV-Her2tg;Rras2þ /
þ animals (Fig. 8d). When tumours developed, they required
longer latencies (Fig. 8d,e), showed lower multiplicity (Fig. 8e)
and were signiﬁcantly smaller (Fig. 8f) and metastatic (Fig. 8g)
than those from control mice. To assess the status of ‘non-
tumorigenic’ glands, we isolated inguinal mammary glands from
these cohorts of mice that, according to visual and palpation
examination criteria, had not developed any physical sign of
tumour outgrowth. Whole-mount and histological analyses
revealed marked differences in the histology of these ‘non-
tumorigenic’ glands. Thus, whereas a large percentage (E70%) of
inguinal glands from MMTV-Her2tg;Rras2þ /þ animals dis-
played extensive secondary ductal branching, increased numbers
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of lobulo-alveolar terminal units and cystic dilatation, the ‘non-
tumorigenic’ ones from MMTV-Her2tg;Rras2 / animals only
exhibited such hyperplasic phenotype in 30% of the cases
examined (Fig. 8h,i). Taken together, these observations indicate
that R-Ras2 plays important roles during Her2-induced mam-
mary gland morphogenesis and tumorigenesis.
R-Ras2 deﬁcient tumours develop compensatory mechanisms.
Tumours from control and MMTV-Her2tg;Rras2 / mice were
collected to analyse the phosphorylation and expression status of
speciﬁc signalling routes typically involved in Ras and R-Ras2
transformation. Unexpectedly, we found using western blot
analyses that seven out of the eight tumours obtained from
MMTV-Her2tg;Rras2 / mice showed various levels of
Erk1/2 hyperphosphorylation (Fig. 8j, top panels, compare lanes
1–5/10–13 with 6–9/14–17). This was corroborated using
immunohistochemical analyses with phospho-Erk1/2 antibodies
(Supplementary Fig. 9a). Such upregulation was only observed in
two out of the nine tumours obtained from control mice (Fig. 8j,
top panels; Supplementary Fig. 9a). Further analysis indicated
that Erk1/2 and Mek1/2 phosphorylation levels were usually, but
not always co-regulated in the same tumour samples (Fig. 8j,
third panel from top). A more limited number of MMTV-
Her2tg;Rras2 / mouse-derived tumours (50%) also showed
increased amounts of phospho-Akt (Fig. 8j, fourth panel from
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length (middle) and terminal end bud (TEB) numbers (right) of glands from mice of indicated ages and genotypes (n¼ 5). *Pr0.05; **Pr0.01;
***Pr0.001 relative to appropriate control; t-test. (c) Phosphorylation and expression status of indicated proteins in EGF-stimulated MECs obtained from
6-month-old female mice. (d) Tumour-free survival of MMTV-Her2tg;Rras2þ /þ (n¼ 20) and MMTV-Her2tg;Rras2 / (n¼ 22) mice. ***Pr0.001
relative to controls at the ﬁnal experimental time point; t-test. (e) Tumour per mouse average in MMTV-Her2tg;Rras2þ /þ (n¼ 20) and MMTV-Her2tg;
Rras2 / (n¼ 22) mice. ***Pr0.001 relative to controls at the ﬁnal experimental time point; t-test. (f) Average size of tumours developed in MMTV-
Her2tg;Rras2þ /þ (n¼ 20) and MMTV-Her2tg;Rras2 / (n¼ 22) mice. **Pr0.01 relative to controls at the ﬁnal experimental time point; t-test. In b, d, e
and f, values are given as mean±s.e.m. (g) Mean percentage of tumour-bearing mice with lung metastases. (h) Representative whole mount-stained
(top panels; scale bar, 500 mm) and haematoxylin/eosin-stained (bottom panels; scale bar, 100 mm) samples from inguinal, ‘non-tumorigenic’ mammary
glands from indicated mice (top). White asterisks, inguinal lymph nodes; white arrowhead, example of a small adenocarcinoma; black asterisk, example of
cystic dilation; black arrowheads, examples of hyperplasic lobulo-alveolar units. (i) Quantiﬁcation of hyperplasic parameters in ‘non-tumorigenic’
mammary glands from indicated mice. Grade 0, no hyperplasia; grade 1, glands with ductal ramiﬁcations, lobulo-alveolar terminal units or cystic dilatations;
grade 2, glands showing at least two of those hyperplasic parameters. n¼ 15 and 21 control, and MMTV-Her2tg;Rras2 / mice, respectively.
(j) Phosphorylation and expression status of indicated proteins (left) in tumour samples (top) obtained from control and MMTV-Her2tg;Rras2 / mice.
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top). Elevated phosphorylation of S6RP was also observed in
some of those tumours (Fig. 8j, sixth panel from top). However,
this event correlated better with the phospho-Erk rather than
with the phospho-Akt status of those tumours (Fig. 8j, compare
ﬁrst, fourth and sixth panels). Analysis of these tumours indicated
that this compensatory mechanism was unrelated to the devel-
opment of oncogenic mutations in Kras or Braf proto-oncogenes
(Supplementary Table 3) or to changes in expression of trans-
cripts for either H-Ras or Erk phosphatases (Dusp1, Dusp2)
(Supplementary Fig. 9b). We did observe cases of upregulation of
the Kras mRNA in some of the samples analysed (Supplementary
Fig. 9b). However, this parameter did not correlate with the
amount of phospho-Erk found in the same tumour samples. The
development of this signalling feature was not due to the direct
activation of signalling crosstalk in pre-malignant stages, because
MECs obtained from prepubertal MMTV-Her2tg;Rras2 / mice
(see above, Fig. 8c) and standard Rras2 / mice18 do not show
this signalling signature.
Discussion
R-Ras2 attracted signiﬁcant interest on its discovery due to its
high similarity to classical Ras GTPases. Despite this, we still have
very little information about the actual role of endogenous
R-Ras2 in tumours and the level of functional overlap with Ras
proteins. To tackle those issues, we decided to use knockdown
cancer cells, primary MECs and Rras2 / mice to assess the role
of endogenous R-Ras2 in a number of breast cancer experimental
models. In addition, we selected cancer cell lines that made it
possible the direct examination of R-Ras2 function in the context
of constitutive signalling from classical Ras GTPases. This
multifaceted strategy revealed that endogenous R-Ras2 plays
key functions during both primary breast tumorigenesis and late
metastatic disease in the lung (Supplementary Fig. 10). However,
these roles change signiﬁcantly depending on the cell background
and signalling process analysed. For example, we have observed
that R-Ras2 can drive primary tumorigenesis in a signalling
autonomous manner. By contrast, it requires parallel signals from
other oncogenic pathways to favour metastatic traits in both
MECs and immortalized cancer cells (Supplementary Fig. 10).
The lack of functional autonomy of R-Ras2 in this latter process is
probably a reﬂection of its speciﬁc involvement in post-
extravasation metastatic stages, a feature that necessarily imposes
the need of other oncogenic signals to favour the acquisition of
earlier prometastatic traits such as efﬁcient intravasation, survival
behaviour in the circulation and extravasation properties. We
have also found that R-Ras2 can drive primary tumorigenesis
with (in the case of MECs) or without (in the case of
immortalized cancer cells) parallel effects in mitogenic properties
of cells, emphasizing the cell background-speciﬁc roles of this
GTPase (Supplementary Fig. 10). Our results have also
unexpectedly revealed that R-Ras2 and classical Ras proteins
work non-redundantly in breast cancer cells. We have demon-
strated that part of such functional segregation involves the
differential stimulation of the PI3Ka/Akt and Raf/Mek/Erk
signalling axes by those proteins, respectively (Supplementary
Fig. 10). Although challenging the signalling dogma holding that
the GTPase-dependent stimulation of PI3Ka is mostly mediated
by direct physical interactions with oncogenic Ras proteins33,
these results are consistent with previous data indicating that the
PI3Ka/Akt axis can be activated in Ras-independent manners in
some Ras-transformed cells16,24,34–37. Interestingly, the inﬂuence
of R-Ras2 on the PI3K/Akt pathway is highly dependent on the
experimental conditions used. Thus, we have seen that ectopically
expressed R-RAS2G23V promotes a marked upregulation of PI3K-
dependent routes in all cell models analysed. By contrast, the
depletion of the endogenous protein only affects the activation of
a relatively small pool of the total PI3Ka present in breast cancer
cells. As a consequence, we have observed that these cells only
exhibit in vitro defects in protein biosynthesis, one of downstream
responses regulated by the PI3K/Akt/mTORC route in cells. This
is not entirely unexpected given that most cells can stimulate
PI3Ka through different mechanisms, including the GTPase-
independent physical interaction of PI3Ka/p85PI3K complexes
with upstream receptors38. Despite this, the R-Ras2-dependent
PI3Ka pool is clearly relevant in vivo, given the marked
tumorigenic and metastatic defects shown by R-Ras2-deﬁcient
breast cancer cells when implanted in recipient mice. The
morphogenetic alterations seen in preneoplasic mammary glands
of MMTV-Her2tg;Rras2 / mice, together with the signalling
compensation events detected in tumours arising in those mice,
are also indirect evidence in favour of defects in the PI3Ka/Akt/
mTORC route in this experimental model30,31,39–45. However, as
reconstitution experiments are not possible in this case, we
cannot formally exclude the possibility that those events could be
generated by defects in other R-Ras2-dependent signalling routes
(Supplementary Discussion).
Our results have revealed that R-Ras2 has to regulate other
PI3Ka-independent signalling routes to maintain the metastatic
properties of 4T1 cells (Supplementary Fig. 10). This is consistent
with recent observations indicating that full-blown metastasis in the
lung parenchyma requires the coordinated and stepwise assembly
of multiple biological programmes46. Unlike the case of 4T1 cells,
we have observed that MDA-MB-231-Luc cells can acquire
metastatic traits by just enforcing the stimulation of the PI3K/Akt
axis through the expression of active versions of either R-RAS2 or
PI3Ka. These two sets of results are not contradictory, as the rescue
experiments performed in these two cell lines measure independent
biological parameters. In the case of Rras2-knockdown 4T1 cells,
the ectopic expression of proteins is used to eliminate defects
directly derived from the loss of endogenous R-Ras2 and, therefore,
the results obtained can be directly used to infer the intrinsic
signalling properties of R-Ras2 in the metastatic process. However,
in the case of MDA-MB-231-Luc cells, the ectopic expression of
proteins is used as a tool to elicit a gain-of-function effect in cells
that have an R-Ras2 route intact. As a consequence, the rescue
experiments give information in this case about the ability of
R-RAS2G23V and PI3KaCAAX to overcome a PI3Ka-dependent
(but R-RAS2-independent) post-extravasation step presumably
defective in MDA-MB-231-Luc cells. Notwithstanding these
results, the ﬁndings obtained in both experimental models clearly
support the speciﬁc implication of PI3Ka as a key downstream
element in the prometastatic signalling pathways of this GTPase.
The results obtained with MMTV-Her2tg mice further under-
score the importance of endogenous R-Ras2 in breast tumorigen-
esis. This model also revealed that the lack of R-Ras2 promotes
signalling compensation mechanisms in tumours similar to those
seen before on the inactivation of speciﬁc PI3K/mTORC route
signalling elements39–45. In those cases, such compensation
effects are mostly mediated by the elimination of mTORC-
dependent negative feedbacks on the Raf/Erk route39–45.
However, the development of these signatures in MMTV-
Her2tg;Rras2 / mice seems to require long-term Darwinian
selection events, because primary MECs from both MMTV-
Her2tg;Rras2 / (this work) and Rras2 / knockout mice18 do
not exhibit such signatures. Evidence for selection events
favouring breast tumour recurrence do exist in the literature.
Those include, for example, the ampliﬁcation of Met, Erbb3 (also
known as Her3),Myc and eiF4E genes45,47. It will be interesting to
characterize the genome of Her2tg;Rras2 / tumours in the near
future to verify whether they had developed similar or alternative
genetic events during their outgrowth. An inference from these
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results is that R-Ras2-based therapies will probably fail in the
long-term unless combined with drugs that could speciﬁcally
block these signalling compensation events.
Methods
Ethics statement. All animal work has been done in accordance with protocols
approved by the Bioethics committees of both the University of Salamanca and CSIC.
Cell culture. MDA-MB-231-Luc cells were provided by Dr. R. Gomis (Institute for
Research in Biomedicine, Barcelona, Spain) and maintained in DulbeDMEM (Life
Technologies) containing FCS (Life Technologies), 1% L-glutamine (Life Tech-
nologies) and 100 units ml 1 penicillin and streptomycin (Life Technologies). 4T1
cells were obtained from the ATCC and maintained as above in RPMI (Roswell
Park Memorial Institute) media containing 10% FCS, penicillin (10 units ml 1)
and streptomycin (100 mgml 1). The 4OT7 and 168FARN cell lines were gently
provided by Dr. F. Miller (Wayne State University School of Medicine, Detroit,
MI)25 and maintained as indicated for 4T1 cells. For cell stimulation studies, cancer
cell lines were serum-starved for either 24 h (MDA-MB-231-Luc cells) or 4 h (4T1
cells), and then stimulated with EGF (20 ngml 1, Sigma) or IGF1 (50 ngml 1,
Sigma) for the indicated periods of time. For the evaluation of the effect of PI3K
inhibitors, serum-starved cells were incubated in serum-free media for 1 h with
20mM LY294002 (Calbiochem), 1 mM PIK-75 (Cayman Chemical), 0.5 mM TGX-
221 (Cayman Chemical), 5 mM IC-87114 (Cayman Chemical) or 0.5 mM AS-
252424 (Cayman Chemical). Stock solutions for all those PI3K inhibitors were
prepared in dimethylsulphoxide. According to the IC50 values for each compound,
PIK-75 must inhibit PI3Ka (IC50¼ 5.8 nM) and, to a much lesser extent, PI3Kg
(IC50¼ 0.076mM) and PI3Kb (IC50¼ 1.3 mM) in experiments performed in this
work. TGX-221 is regarded as a PI3Kb-speciﬁc inhibitor48. IC-87114 must inhibit
PI3Kd (IC50¼ 0.5 mM) while preserving the activity of both PI3Kg (IC50¼ 29 mM)
and PI3Kb (IC50¼ 75mM). According to previous data, this drug should not
inhibit PI3Ka even if used at higher concentrations than those used in our in vivo
experiments49. The AS-252424 compound must inhibit PI3Kg (IC50¼ 30 nM) and,
to a much lesser extent, PI3Ka (IC50¼ 0.94 mM). By contrast, it should not have
signiﬁcant effects on either PI3Kb (IC50¼ 20mM) or PI3Kd (IC50¼ 20 mM).
MECs were obtained from 8- to 12-week-old FVB mice. To this end, mammary
glands 3, 4 and 5 were isolated, minced with a 22 scalpel for 3min and digested in
DMEM:F12 supplemented with 5% FCS, 2mgml 1 Clostridium histolyticum
collagenase (Sigma), 100mgml 1 streptomycin, 100 units ml 1 penicillin) for 1 h
at 37 C under moderate shaking. Mammary organoids were separated from fat
and single cells (such ﬁbroblasts and red cells) by 600 g centrifugation steps lasting
10min (one), 5min (one), and 2 s (four). After each centrifugation step, cell pellets
were resuspended in DMEM:F12 medium. Puriﬁed organoids were then
trypsinized (0.5mgml 1 trypsin and 0.2mgml 1 EDTA in saline solution;
Invitrogen) for 20min at 37 C, washed with DMEM:F12, incubated with DNAseI
(4 units ml 1 in DMEM:F12, Sigma) for 3min at 25 C and ﬁltered through a 70-
mm cell strainer (BD Falcon). Cells were cultured in MEC primary growth medium
(DMEM:F12 media containing 10% FCS, 5 mgml 1 insulin, 5 ngml 1 EGF
(Sigma), 100 mgml 1 streptomycin, 100 units ml 1 penicillin and 50mgml 1
gentamicin) from passages 0 to 2. For growth factor stimulation, MECs were
incubated for 4 h in starvation medium (MEC primary growth medium lacking
mitogens and containing 0.5% FCS) and then 5 nM EGF was added.
To generate cultures from PyMT-induced breast tumours, a piece (E1 cm3) of
the periphery of the tumour mass was dissected, minced with a 22 scalpel for 3min
and digested in DMEM:F12 supplemented with 5% FCS, 2mgml 1 Clostridium
histolyticum collagenase (Sigma), 100 mgml 1 streptomycin, 100 unitsml 1
penicillin) for 1 h at 37 C under moderate shaking. Cells were then spun down and
trypsinized (0.5mgml 1 trypsin and 0.2mgml 1 EDTA in saline solution;
Invitrogen) for 20min at 37 C, washed with DMEM:F12 (Invitrogen), and
incubated with DNAseI (4 unitsml 1 in DMEM:F12, Sigma) for 3min at 25 C.
After being ﬁltered through a 70-mm cell strainer (BD Biosciences/Falcon), cells
were cultured in DMEM:F12 media containing 10% FCS, 5 mgml 1 insulin,
5 ngml 1 EGF, 100mgml 1 streptomycin, 100 units ml 1 penicillin and
50mgml 1 gentamicin) from passage 0 to passage 2.
Western blot analyses. Protein samples were separated electrophoretically and
transferred onto nitrocellulose ﬁlters using the iBlot Dry Blotting System (Invi-
trogen). Membranes were blocked in either 5% non-fat dry milk (when immu-
noblotted with standard antibodies) or 5% BSA in (Sigma, when using phospho-
speciﬁc antibodies) in TBS-T (25mM Tris-HCl (pH 8.0), 150mM NaCl, 0.1%
Tween-20) for 1 h and then incubated overnight at 4 C with appropriate primary
antibodies (see Supplementary Table 4) diluted in blocking buffer. After three
washes with TBS-T, the membrane was incubated with horseradish peroxidase-
conjugated Protein A (Thermo Scientiﬁc) or the appropriate secondary antibody
(Thermo Scientiﬁc, 1:5,000 dilution) for 1 h at room temperature. Immunoreacting
bands were developed using a standard chemoluminescent method (Thermo Sci-
entiﬁc). When indicated, ﬁlms were scanned and immunoblot-derived signals
quantiﬁed using the ImageJ software (National Institutes of Health). Full size
images of blots are shown in Supplementary Figs. 11–17.
Animal studies. For long-term tumorigenic experiments with cell lines, MDA-
MB-231-Luc cells were trypsinized, resuspended in complete medium, counted,
pelleted by centrifugation, washed once with ice-cold PBS, re-pelleted and resus-
pended (2 107 cell per ml) in a an ice-cold 50:50 solution of Matrigel (Growth
Factor Reduced and Phenol Red-free; reference: 356231; BD Biosciences) and PBS.
Fifty microlitres of the ﬁnal cell suspension (1 106 cells) were introduced into the
right inguinal mammary gland of anaesthetized, age-matched 4–6-week-old female
NOD/SCID mice using a 25-gauge needle. 4T1 (usually 3,000 cells per implant,
except in Supplementary Fig. 3f in which we used 500,000 cells per implant), 4TO7
(500,000 cells per implant) and 168FARN (500,000 cells per implant) were
introduced in mammary fat pads as above. Tumour growth in each case was
quantiﬁed by taking measurement of the tumour length (L), width (W) and depth
(D). These parameters were then used to calculate the total tumour volumes at
experimental time point using the mathematical formula: tumour volume¼
pLWD/6. Alternatively, tumour growth was assessed using as read-out the biolu-
minescence generated by the luciferase stably expressed by MDA-MB-231-Luc
cells. To that end, orthotopically transplanted mice were injected intraperitoneally
(150 mg g 1 of body weight) at the indicated time points with a D-luciferin
(Promega) solution in PBS, anaesthetized with isoﬂuorane and imaged using an
IVIS system (Xenogen) coupled to Living Image Acquisition and Analysis software
(Xenogen). Images were taken within the ﬁrst 10min after D-luciferin adminis-
tration. Metastatic dissemination in tumour-bearing mice was quantiﬁed by both
visually (in extracted lungs using a magnifying lens) and histologically (using tissue
sections and standard light microscopy techniques) after killing the mice at the end
of the in vivo tumorigenic experiments.
To carry out direct, long-term lung colonization assays, 500,000 (50,000 in the
case of Fig. 2d,e) cells were resuspended in PBS as above and injected into the
lateral tail vein. After 2 weeks, mice were euthanized, the chest cavity exposed
through a midline chest incision, the trachea cannulated with a 20-gauge caterer
and lungs slowly inﬂated using 1ml of India ink (Parker, 1:16 dilution in PBS).
Lungs were extracted, immersed in Fekete’s solution (100ml 70% ethanol (Sigma),
10ml 4% formaldehyde (Leica) and 5ml 100% glacial acetic acid (Sigma)) to
destain, and the metastatic nodules were counted by visual observation.
Alternatively, lungs were extracted, ﬁxed in 4% formaldehyde and embedded in
parafﬁn for haematoxylin/eosin staining. Metastasis of MDA-MB-231-Luc cells
were determined either by visual or bioluminiscence methods as above. In the case
of assays with cancer cells derived from PyMT-expressing mammary tumours (see
below), cells were resuspended in 100ml PBS and injected (1 106 cells) into the
tail vein of NOD/SCID female mice (Charles River) age-matched between 6 and 8
weeks. After 7 weeks, mice were euthanized, lungs extracted and metastatic nodules
scored as above.
To quantitate the dissemination of cancer cells to lymph nodes in tumour-
bearing animals, we extracted total RNA from indicated lymph nodes using Trizol
(Sigma) and the presence of circulating tumour cells indirectly estimated by qRT–
PCR. This was done by calculating the abundance of the mRNA for the puromycin
resistance gene (present exclusively in the 4T1 cells used in this study) in relation to
that of an endogenous mouse mRNA (B2m). Primers used in these experiments are
shown in Supplementary Table 5. Values were corrected according to the
expression of the viral gene in each cell line when maintained in tissue culture.
To measure intravasation, we collectedE1ml of blood from the heart atrium of
the same tumour-bearing mice, pelleted the circulating cells by centrifugation, lysed
red cells using two lysis cycles in ACK buffer (BD Biosciences/Gibco) and extracted
total RNAs using Trizol to quantify the presence of circulating tumour cells
through qRT–PCR as above.
To measure the extravasation of breast cancer cells, the indicated cell lines were
labelled with 5 mM of a green cell tracker (CellTracker green CMFDA, Invitrogen)
for 1 h and injected intravenously into mice (1 106 cells per mice). After 48 h,
mice were injected intravenously with a rhodamine-conjugated lectin (Vector
Laboratories) to stain lung capillaries and killed 60min later. Lungs were then
extracted, ﬁxed in paraformaldehyde and examined by confocal ﬂuorescence
microscopy to visualize the number of cancer cells (green colour) present in the
lung.
For Her2-based tumorigenesis experiments, we crossed Rras2 / knockout50
and MMTV-Her2tg transgenic (FVB/NTg(MMTVneu)202 Mul/J strain; The
Jackson Laboratory) mice to generate the compound MMTV-Her2tg;Rras2 mouse
strain. The new strain was homogenized in the FVB background. For long-term
tumorigenic experiments, mice were monitored for tumour development weekly as
above. Experiments were ﬁnished when animals were 1 year old or, alternatively,
when exhibiting either very large tumours or obvious signs of discomfort. At this
time, the number of lung metastases was also determined visually as indicated
above. In some cases, we also isolated mammary glands for histological
examination that, according to palpation and visual examination, had not formed
tumours during the above long-term tumorigenesis experiment. These glands
indistinctly belonged to either tumour-free mice or to animals that had tumours in
other mammary glands (that is, thoracic). These samples are referred to in main
text as ‘non-tumorigenic’.
Immunohistochemistry. Depending on the experiment, the histology-related
work was performed by independent personnel at the Histopathology units of
either our Center or CNIO’s (Madrid, Spain). To this end, tissues were extracted,
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ﬁxed in 4% paraformaldehyde (Sigma), cut in 2–3-mm-thick sections, and stained
with haematoxylin/eosin. Proliferation and angiogenesis were monitored by
immunohistochemical staining of tumour section with antibodies to Ki67 and
CD31, respectively18,51. Apoptotic cells were detected using either TUNEL (TdT-
mediated dUTP nick end labelling) labelling or cleaved caspase 3
immunostaining18. Additional immunohistochemical stainings were performed
using a mouse monoclonal antibody to p53 (dilution 1:200; clone PAb 240, Abcam)
and rabbit polyclonal antibodies to both phospho-T24 FoxO1 and phospho-T32
FoxO3a (dilution 1:10; catalogue number 9464, Cell Signaling Technology),
phospho-S240/244 S6RP (dilution 1:50; catalogue number 2215, Cell Signaling
Technology) and phospho-Erk1/2 (dilution 1:400; catalogue number 9101, Cell
Signaling Technology). For mammary gland development studies, mammary fat
pads were extracted from animals of the indicated age, placed on dry, silanized
glass slides and ﬁxed overnight in Carnoy’s ﬁxative (1:3:6 parts of glacial acetic
acid:chloroform:100% ethanol). Tissues were rehydrated through successive
incubations with 70% ethanol followed by distilled water and then stained with Red
Carmine overnight. Mammary glands were analysed with a stereomicroscope
(SMZ800, Nikon) and acquired with a digital camera (Digital Sight DS-Fi1, Nikon).
The mammary gland area was obtained by calculating the area occupied by a lane
drawn around the gland, including the nipple. The mammary gland length was
measured from the end of the longest duct to a reference median point located
between the nipple and the adjacent lymph node. In both cases, the analyses were
carried out using ImageJ software (National Institutes of Health). Number of
terminal end buds and branching points were counted using photomicrographs of
the entire gland.
Analysis of mRNA abundance. Total RNAs were extracted using the RNeasy
mini kit (Qiagen) and expression levels of transcripts determined by qRT–PCR
using the QuantiTect SYBR Green RT–PCR kit (Qiagen) and a qRT–PCR appa-
ratus (StepOnePlus Real-Time PCR System cycler, Applied Biosystems). Primers
used for mRNA quantitation are described in Supplementary Table 5. For nor-
malization purposes, we measured in parallel the abundance of the endogenous
transcript for human and mouse GAPDH (Supplementary Table 5). Raw data were
analysed using the StepOne software v2.1 (Applied Biosystems).
In vitro proliferation and survival determinations. We used the MTT (3-(4,5-
dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide) assay (Sigma) to deter-
mine the growth properties of cancer cells under study. To this end, cells were
plated onto 24-well dishes (7,000 cells per well) and cultured in RPMI supple-
mented with 10% calf serum for the indicated periods of time. At the indicated
time point, the culture medium of each well was discarded and replaced by 250 ml
of an MTT solution (0.5mgml 1) in PBS. After 1 h at 37 C in a 5% CO2
atmosphere, 500 ml of dimethyl sulphoxide (Sigma) per well were added to dissolve
the formazan crystals formed and the absorbance at the 570 nm wavelength
measured 15min later using a microplate reader (Ultraevolution, Tecan). In the
case of MECs, aliquots of 20 103 MECs (passage 0–2, see above) were plated onto
six-well culture plates and cultured in MEC primary growth medium. At the
indicated time points, cells were trypsinized and counted. Alternatively, 5-bro-
modeoxyuridine incorporation assays were performed using a commercial kit (Cell
Proliferation ELISA, Roche) according to the manufacturer’s instructions. To carry
out three-dimensional culture studies, cells were trypsinized, washed, resuspended
as a single-cell suspension in growth factor-reduced Matrigel and cultured in either
starvation medium (MEC primary growth medium lacking mitogens and con-
taining 0.5% FCS) or, alternatively, in standard MEC primary growth medium
supplemented when needed with indicated drugs. After 10 days, bright-ﬁeld pic-
tures of cell colonies were acquired using an inverted microscope (Axiovert 135,
Zeiss) coupled to a digital camera (C2724-95, Hamamatsu). After measuring the
diameter (D) of the cell colonies using ImageJ software, the volume of colonies (V)
was calculated using the following mathematical formula: V¼ 4.p.(D/2)3/3. When
indicated, 0.2 mM wortmannin (Calbiochem) or 40mM PD98059 (Calbiochem)
were included in culture media. For cell survival determinations, cancer cells were
seeded in either complete or serum-free media using both standard (at 25 104
cells per well) and ultra-low attachment surface six-well plates (5 105 cells per
well) obtained from Corning. After either 24 h (in the case of 4T1 cells) or 48 h (in
the case of MDA-MB-231-Luc cells), the percentage of viable cells was evaluated by
ﬂow cytometry using the Annexin V–ﬂuorescein isothiocyanate apoptosis detec-
tion kit (Immunostep).
Protein synthesis determinations. Subconﬂuent, exponentially growing cells
were maintained for 20min in methionine-free DMEM (Life Technologies),
washed once in PBS and re-cultured in methionine-free DMEM. After 20min, cells
were pulsed with 10mCi of EasyTag L-[35S]-Methionine (PerkinElmer). At the
indicated periods of time, proteins were extracted using ice-cold lysis buffer
(20mM Tris-HCl (pH 7.4), 150mM NaCl, 1% Nonidet-P40 (Sigma), 0.5% sodium
deoxycholate (Sigma), 1mM b-glycerophosphate (Sigma), 1mM Na3VO4 (Sigma),
50mM NaF (Sigma) and a protease inhibitor cocktail (Cfmplete, Roche)), sepa-
rated electrophoretically in 10% SDS–PAGE gels and transferred onto nitrocellu-
lose ﬁlters using an iBlot Dry Blotting System (Invitrogen). After autoradiograph
exposure of ﬁlters at  70 C, the total amount of radiolabelled proteins was
determined indirectly by densitometry analysis of autoradiography ﬁlms using the
ImageJ software.
Polysome analyses were performed adapting a procedure previously described
for Sachharomyces cerevisiae52. To this end, 6-8 107 cells were grown in 150mm
dishes to 80% conﬂuency and, immediately before harvesting, treated with
cycloheximide (0.1mgml 1, Sigma) for 5min at 37 C. Cells were washed twice
with ice-cold PBS containing 0.1mgml 1 cycloheximide and scraped off from
plates using 2ml of the same solution and a rubber policeman. Cells were collected
by centrifugation and lysed by vortexing in 400 ml of polysome-proﬁle lysis buffer
(10mM Tris-HCl (pH 7.5), 60mM NaCl, 15mM mgCl2, 0.5% Triton X-100
(Sigma), 0.1mgml 1 cycloheximide and 1mgml 1 heparine [Sigma]). After pre-
clearing by high-speed centrifugation for 10min at 4 C, cell extracts equivalent to
5 absorption units at 260 nm were layered onto 7–50% sucrose gradients (10ml),
which had been prepared in 50mM Tris-acetate (pH 7.5), 50mM NaCl and 1mM
dithiothreitol. Ultracentrifugation was performed in a SW40 rotor (Beckman) at
39,000 r.p.m. for 165min at 4 C. Polysome proﬁles were obtained in a gradient
reader apparatus (Brandel) by continuous reading of absorbance at 254 nm from
the top to the bottom of each gradient.
Genomic DNA sequencing. Genomic DNA was extracted from samples of the
mouse breast tumours shown in Fig. 8j using the QIAamp DNA micro kit (Qiagen)
and sequences for Kras (exon 1) and Braf (exon 15) genes PCR ampliﬁed using
appropriate oligonucleotides (Supplementary Table 5). PCR products were
sequenced at the Genomics and Proteomics Unit of our Center.
Image processing. Images were assembled and processed for ﬁnal ﬁgure pre-
sentation using Canvas 9.0.4 (Deneba Systems).
Statistics. Statistical analyses were performed using the two-tailed Student’s t-test
for paired and impaired data versus control values or, in other cases, the analysis of
variance. Sample size was chosen to obtain statistically signiﬁcant conclusions. No
samples were excluded from analyses. With the exception of immunohistochemical
data, score of experiments was not done blindly. Results with a P-valuer0.05 were
considered as statistically signiﬁcant.
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